XML 29 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2

OPERATING EXPENSES

12 Months Ended

Mar. 31, 2022

Operating Expenses

OPERATING EXPENSES

4. OPERATING EXPENSES

Operating expenses are stated after charging:

DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY 

Group			2022 $				2021 $				2020 $
		Year Ended March 31,
Group			2022 $				2021 $				2020 $
Director fees including bonus (excluding Chairman’s bonus)			707,385				278,224				122,101
Chairman’s bonus			-				1,160,347				-
Auditor’s Remuneration (refer to Note 20) *			349,665				131,511				53,402
Legal and Professional fees			1,143,300				343,422				195,433
(Gain)/Loss on disposal of leases			(179	)			-				-
FX Gains and losses			(13,577	)			200,061				200,061
Depreciation			2,423				1,512				212

* This has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the company’s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements. Refer to note 20 where details of auditor’s remuneration has been disclosed. This has no impact on the primary financial statements.

X

- References

No definition available.

+ Details

Name:	OKYO_DisclosureOperatingExpensesAbstract
Namespace Prefix:	OKYO_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of other operating expense. [Refer: Other operating income (expense)]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 10
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration